Rhumbline Advisers Reduces Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Rhumbline Advisers decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 658,357 shares of the medical research company's stock after selling 6,255 shares during the period. Rhumbline Advisers owned approximately 0.17% of Thermo Fisher Scientific worth $327,598,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Cypress Advisory Group LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $253,000. Intact Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 34.0% during the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after purchasing an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $1,121,000. Independence Bank of Kentucky boosted its stake in shares of Thermo Fisher Scientific by 21.0% during the fourth quarter. Independence Bank of Kentucky now owns 3,825 shares of the medical research company's stock valued at $1,990,000 after acquiring an additional 663 shares during the last quarter. Finally, W.H. Cornerstone Investments Inc. raised its stake in Thermo Fisher Scientific by 25.1% in the 4th quarter. W.H. Cornerstone Investments Inc. now owns 2,870 shares of the medical research company's stock valued at $1,493,000 after purchasing an additional 576 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Royal Bank of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Scotiabank reduced their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a report on Friday, April 25th. UBS Group reduced their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Finally, Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $605.30.

Thermo Fisher Scientific Stock Down 0.2%

Thermo Fisher Scientific stock traded down $0.67 during midday trading on Thursday, reaching $402.99. The stock had a trading volume of 970,219 shares, compared to its average volume of 1,892,656. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm's fifty day simple moving average is $424.35 and its 200-day simple moving average is $497.38. The stock has a market capitalization of $152.13 billion, a P/E ratio of 24.38, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.11 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Insider Activity

In related news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.